Global Chemotherapy-Induced Neutropenia Treatment Market Projected to Reach $0.76 Billion by 2029 at a CAGR of 5.3%
We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Are the Key Milestones in the Chemotherapy-Induced Neutropenia Treatment Market’s Growth Trajectory From 2025 To 2034?
The market size for treatment of neutropenia induced by chemotherapy has seen substantial growth recently. Its value is projected to rise from $0.59 billion in 2024 to $0.62 billion in 2025, marking a compound annual growth rate (CAGR) of 5.7%. Factors contributing to the historic period growth include a swell in cancer diagnosis, enhanced acceptance of chemotherapy, aging population, increased hospitalization due to infections, and expanding pipelines of oncology drugs.
The market size for the treatment of chemotherapy-induced neutropenia is predicted to witness substantial growth in the forthcoming years. By 2029, it is anticipated to reach $0.76 billion with a 5.3% compound annual growth rate (CAGR). This estimated growth within the specified period can be ascribed to an escalating demand for targeted neutropenia treatments, an increased investment in cancer research and development, an intensified focus on out-patient care, a broadening use of biosimilars, and heightened knowledge on infection prevention. The key trends anticipated during this forecast period encompass the evolution of long-acting granulocyte colony-stimulating factor (G-CSF) therapies, a growing application of combination treatments, an elevated preference for in-home care solutions, a rise in biosimilar approvals, and the incorporation of digital health monitoring tools.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What are the Fundamental Drivers and Innovations Shaping the Chemotherapy-Induced Neutropenia Treatment Market?
The escalated prevalence of cancer is anticipated to drive the expansion of the chemotherapy-induced neutropenia treatment market. Cancer encompasses a range of illnesses that manifest in the erratic growth and dissemination of abnormal body cells. The surge in cancer incidences can be attributed to the elderly population, who are more susceptible to cancer due to accrued genetic alterations and diminished immunity. Chemotherapy-induced neutropenia therapies contribute to cancer management by diminishing the risk of infections via immune reinforcement, facilitating uninterrupted chemotherapy sessions. This boosts treatment results by reducing complications, thus enhancing patient safety and life quality. For instance, in July 2024, the Australian Institute of Health and Welfare, a government body in Australia, reported that the diagnosed cancer cases in Australia increased to 160,570 in 2022, marking a rise of 3,789 cases from 156,781 in 2021. As a result, the rising cancer prevalence is fueling the expansion of the chemotherapy-induced neutropenia treatment market.
How Is the Chemotherapy-Induced Neutropenia Treatment Market Segmented?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented –
1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
Which Regions Are Driving the Next Phase of the Chemotherapy-Induced Neutropenia Treatment Market Growth?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Chemotherapy-Induced Neutropenia Treatment Market?
The chemotherapy-induced neutropenia treatment market is currently dominated by key players who are working towards the development of innovative products and seeking approvals, such as long-acting formulas, to better patient convenience, lessen the frequency of dosing, and improve treatment adherence. Long-acting formulations are referred to as drug production that gradually release active constituents over an elongated span, thus decreasing the need for frequent administration. For example, Coherus BioSciences Inc., an American biopharmaceutical establishment, was granted approval by the U.S. Food and Drug Administration (FDA) in December 2023 for Udenyca Onbody, a pioneering, ready-to-use on-body injector. This device possesses a long-acting formula that is able to automatically release pegfilgrastim about 27 hours post chemotherapy, hence negating need for an injection the following day. Udenyca Onbody upgrades patient experience by providing punctual prophylactic treatment for chemotherapy-induced neutropenia, at the same time lowering the necessity for clinic appointments and enhancing adherence.
View the full report here:
How Is the Chemotherapy-Induced Neutropenia Treatment Market Defined and What Are Its Core Parameters?
Chemotherapy-induced neutropenia treatment is medical management used to help cancer patients whose white blood cell levels drop after chemotherapy. It reduces the duration and severity of neutropenia to prevent infections. The treatment often involves growth factors and chemotherapy dose adjustments, while early intervention supports schedule adherence and enhances patient outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
